A Phase 2 interventional study of Durvalumab and Oleclumab in Resectable, Early-stage and NSCLC, sponsored by MedImmune LLC. Completed at 18 sites in 7 countries. Open to participants aged 18 Years to 102 Years. Per ClinicalTrials.gov, last updated 2022-02-24.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 44th largest by enrollment, is one of 8 that started in 2019, is one of 58 in phase 2, and was the 36th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Australia, Austria, Belgium and 7 more countries
Ages 18+
Idris Bahce · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 102 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 62 · Phase 3 17 · Phase 4 2
First in 2013; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 94 interventional studies. Of the 47 that completed or were terminated, 27 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 90th largest by enrollment of the 137 interventional ones that give a count, is one of 11 that started in 2019, is one of 38 in phase 2, and was the 115th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing durvalumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04465968Phase 3National Cancer Center Hospital EastEfficacy and Safety of CRT, Durvalumab and Surgery for SST | 2027-08-31 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
| NCT04245514Swiss Cancer InstituteMultimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | 2026-12-07 |
| NCT06908070Idris BahceChemoradiotherapy With Surgery Followed by Consolidation Durvalumab | 2026-12-17 |
| NCT05206812Yonsei UniversityWindow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA) non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
and/or histologically-documented NSCLC
Exclusion Criteria:
Active or prior documented or inflammatory disorders. The following are exceptions to this criterion:
History of another primary except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
Drug: Durvalumab
Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
Drug: Durvalumab · Combination Product: Oleclumab
Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
Drug: Durvalumab · Combination Product: Monalizumab
Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
Drug: Durvalumab · Combination Product: Danvatirsen
Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Also known as: MEDI4736
Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Also known as: MEDI9447
Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Also known as: IPH2201
Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Also known as: AZD9150
Major Pathological Response Rate
Major pathological response rate is defined as percentage of participants with \<=10% residual viable tumor cells in the resected specimen.
Time frame: Day 1 through Day 42
Pathological Complete Response (pCR) Rate
The pCR rate is defined as percentage of participants with no residual viable tumor cells in the resected specimen.
Time frame: Day 1 through Day 42
Feasibility to Surgery
Feasibility to surgery is defined as the percentage of participants who underwent the planned surgery within Days 29 to 42 after Week 1 Day 1.
Time frame: Day 29 to Day 42 after Week 1 Day 1
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: From Day 1 through Day 105
Number of Participants With Grade 3 or Grade 4 Clinical Laboratory Toxicities
Participants with Grade 3 or Grade 4 clinical laboratory toxicities are reported. Laboratory tests included hematology, coagulation, chemistry, and urinalysis.
Time frame: From Day 1 through Day 105
Number of Participants With Abnormal Vital Signs Reported as TEAEs
Participants with abnormal vital sign reported as TEAEs are reported.
Time frame: From Day 1 through Day 105
The trial was interrupted due to COVID-19 pandemic from 13Apr2020 to 07May2020.
| Milestone | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Started | 27 | 21 | 20 | 16 |
| Treated | 26 | 21 | 20 | 16 |
| Completed | 26 | 18 | 19 | 15 |
| Not completed | 1 | 3 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Major pathological response rate is defined as percentage of participants with \<=10% residual viable tumor cells in the resected specimen.
| Percentage of participants | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Major Pathological Response Rate | 11.1 (2.4 to 29.2) | 19.0 (5.4 to 41.9) | 30.0 (11.9 to 54.3) | 31.3 (11.0 to 58.7) |
The pCR rate is defined as percentage of participants with no residual viable tumor cells in the resected specimen.
| Percentage of participants | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Pathological Complete Response (pCR) Rate | 3.7 (0.1 to 19.0) | 9.5 (1.2 to 30.4) | 10.0 (1.2 to 31.7) | 12.5 (1.6 to 38.3) |
Feasibility to surgery is defined as the percentage of participants who underwent the planned surgery within Days 29 to 42 after Week 1 Day 1.
| Percentage of participants | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Feasibility to Surgery | 84.6 (0.1 to 19.0) | 81.0 (1.2 to 30.4) | 90.0 (1.2 to 31.7) | 93.8 (1.6 to 38.3) |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Any TEAEs | 18 | 19 | 15 | 13 |
| Any TESAEs | 3 | 2 | 1 | 5 |
Participants with Grade 3 or Grade 4 clinical laboratory toxicities are reported. Laboratory tests included hematology, coagulation, chemistry, and urinalysis.
| Participants | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Alanine aminotransferase increased | 0 | 0 | 0 | 2 |
| Gamma glutamyl transferase increased | 0 | 0 | 0 | 1 |
| Lipase increased | 1 | 1 | 1 | 0 |
| Hyponatremia | 2 | 0 | 0 | 0 |
| Lymphocyte count decreased | 0 | 0 | 0 | 1 |
Participants with abnormal vital sign reported as TEAEs are reported.
| Participants | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Palpitations | 1 | 0 | 0 | 0 |
| Pyrexia | 1 | 2 | 1 | 0 |
Collected over From Day 1 through Day 105. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab 1500 mg | 0/26 (0%) | 3/26 (11.5%) | 18/26 (69.2%) |
| Durvalumab 1500 mg + Oleclumab 3000 mg | 0/21 (0%) | 2/21 (9.5%) | 19/21 (90.5%) |
| Durvalumab 1500 mg + Monalizumab 750 mg | 0/20 (0%) | 1/20 (5%) | 14/20 (70%) |
| Durvalumab 1500 mg + Danvatirsen 200 mg | 1/16 (6.3%) | 5/16 (31.3%) | 13/16 (81.3%) |
| Event | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| Covid-19Infections and infestations | 0/26 | 0/21 | 0/20 | 1/16 |
| PneumoniaInfections and infestations | 1/26 | 1/21 | 0/20 | 1/16 |
| Wound infectionInfections and infestations | 0/26 | 0/21 | 0/20 | 1/16 |
| Bronchial anastomosis complicationInjury, poisoning and procedural complications | 0/26 | 0/21 | 0/20 | 1/16 |
| Procedural haemorrhageInjury, poisoning and procedural complications | 0/26 | 0/21 | 0/20 | 1/16 |
| Renal infarctRenal and urinary disorders | 0/26 | 0/21 | 0/20 | 1/16 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/26 | 0/21 | 0/20 | 1/16 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/26 | 0/21 | 0/20 | 1/16 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/26 | 0/21 | 1/20 | 0/16 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/26 | 1/21 | 0/20 | 0/16 |
| Event | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg |
|---|---|---|---|---|
| FatigueGeneral disorders | 6/26 | 4/21 | 2/20 | 3/16 |
| Procedural painInjury, poisoning and procedural complications | 5/26 | 0/21 | 0/20 | 0/16 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/26 | 1/21 | 0/20 | 3/16 |
| NauseaGastrointestinal disorders | 2/26 | 3/21 | 0/20 | 1/16 |
| AstheniaGeneral disorders | 3/26 | 3/21 | 0/20 | 0/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/26 | 3/21 | 1/20 | 2/16 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/26 | 0/21 | 0/20 | 2/16 |
| Alanine aminotransferase increasedInvestigations | 1/26 | 0/21 | 0/20 | 2/16 |
| ParaesthesiaNervous system disorders | 0/26 | 0/21 | 1/20 | 2/16 |
| PruritusSkin and subcutaneous tissue disorders | 0/26 | 2/21 | 2/20 | 2/16 |
Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group.
| Age, Continuous(Years) | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 67.1 ± 9.0 | 65.5 ± 7.5 | 65.1 ± 6.3 | 72.9 ± 7.9 | 67.3 ± 8.2 |
| Sex: Female, Male(Participants) | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg | Total |
|---|---|---|---|---|---|
| Female | 13 | 9 | 6 | 6 | 34 |
| Male | 14 | 12 | 14 | 10 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 2 | 3 |
| Not Hispanic or Latino | 26 | 21 | 20 | 14 | 81 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Durvalumab 1500 mg | Durvalumab 1500 mg + Oleclumab 3000 mg | Durvalumab 1500 mg + Monalizumab 750 mg | Durvalumab 1500 mg + Danvatirsen 200 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 1 | 0 | 5 |
| White | 23 | 20 | 19 | 13 | 75 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2019 to primary completion in Jan 2021, 22 months.
Results were first posted in Feb 2022, 1 year 1 month after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab
Carcinoma, Non-Small-Cell Lung →